ARIAD Pharmaceuticals All Financial Data in US $ (mln)

Company News

Bellicum Announces BPX-501 European Regulatory Updates
Bellicum Pharmaceuticals (August 04, 2016)
Weekly Market Movers: Global Majors & Industry (to 29 Jul 2016) (August 01, 2016)
PDL BioPharma Completes Second Tranche Payment Under Royalty Transaction with ARIAD Pharmaceuticals
PDL BioPharma (August 01, 2016)
Daily Market Movers: Global Majors & Industry (28 Jul 2016) (July 29, 2016)
ARIAD Reports Second Quarter and First Half 2016 Financial Results
ARIAD Pharmaceuticals (July 28, 2016)

Displaying 5 out of a possible 901 unique stories.
Results Sorted By date

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2018) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Company Profile

Profile ARIAD Pharmaceuticals (ARIA) is a Massachusetts based biotechnology company focused on development & marketing of anti-cancer drugs that function by regulating the cell signalling pathways.
Listed or Private Company Listed
Company Classification Biotechnology; Genomics
Country USA
Company Website Website
Technology Platform Profile
Full Company Profile Information

PARTNERING OPPORTUNITIES (Click on Product Name for Full Details)

ProductProduct Available for Partnering Opportunity Comment Available USA Available Europe Available Japan Available RoW Markets Detail
Iclusig Yes Company plans for commercialisation of ponatinib on its own in US & potentially in Europe and a regional partnership for the product in select ex-US markets. No Yes Yes Yes WW ex USA
Brigatinib Yes FEB15 Seeking partners for further development. Yes Yes Yes Yes Market undisclosed

Top 3 Products (Worldwide Sales)

Annual Sales WW - Sales Growth per Year (%)
Rank1 ProductProduct Generic NameGeneric Name Therapeutic Subcategory 2013
1 Iclusig ponatinib hydrochloride Other cytostatics 452

Rx Sales Chart

ARIAD Pharmaceuticals Data Growth
2014 2015 2015
  Revenues By Segment
      Pharmaceuticals Sales (In-depth)
        Rx & OTC Pharmaceuticals
         Prescription (Rx) Pharmaceuticals 56 113 102%

Therapy Area Focus

ARIAD Pharmaceuticals
  WW Rx & OTC Sales By Therapy Area
   Main Categories
     Oncology & Immunomodulators 113
     Other Rx & OTC Pharma 0

EvaluatePharma® Coverage of Marketed and Pipeline Products

Product Count
ARIAD Pharmaceuticals 3 42

Note: Daily share prices and certain other per-share data are supplied to EvaluatePharma Ltd by a third party and under the terms of supply are available for on-screen viewing purposes only. Copying these data out of EvaluatePharma is not permitted and such data are masked within downloads into Excel (TM).


Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate


EvaluatePharma® now includes Partnering Opportunities - products available for licensing.

Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.

Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.

Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.

EP Vantage - last 6 months
Incyte’s European invasion (May 10, 2016)

Register to access more FREE content:

  • 2011 Product Sales analysis
  • 2011 Pharmaceutical Sales
  • 2011 Market Share & Global Ranking
  • Download to Excel
  • Search 2 yrs of company press releases

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.

Register Now